1 Department of Radiology, Division of Nuclear Medicine, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8896.
2 Department of Radiology, Mayo Clinic, Rochester, MN.
AJR Am J Roentgenol. 2018 Aug;211(2):267-277. doi: 10.2214/AJR.18.19881. Epub 2018 Jul 5.
The purpose of this article is to provide a review of the use of Ga tetraazacyclododecanetetraacetic acid-DPhe1-Tyr3-octreotate (DOTATATE) PET/CT, a functional imaging modality for assessment of well-differentiated neuroendocrine tumors (NETs). It has become the preferred imaging modality for initial diagnosis, selection of patients for peptide receptor radionuclide therapy, and localization of unknown primary tumors. The National Comprehensive Cancer Network guideline has added Ga-DOTATATE PET/CT as an appropriate test in the management of NETs.
In combination with FDG PET/CT, Ga-DOTATATE PET/CT can noninvasively assess tumor heterogeneity, especially in G2 and G3 NETs, for personalized management of patients.
本文旨在回顾 Ga 四氮杂环十二烷四乙酸-DPhe1-Tyr3-奥曲肽（DOTATATE）PET/CT 的应用，该方法为评估分化良好的神经内分泌肿瘤（NETs）的一种功能成像方式。它已成为初始诊断、肽受体放射性核素治疗患者选择以及未知原发肿瘤定位的首选影像学方法。美国国家综合癌症网络指南已将 Ga-DOTATATE PET/CT 添加为 NETs 管理中的合适检查。
与 FDG PET/CT 相结合，Ga-DOTATATE PET/CT 可无创性评估肿瘤异质性，尤其是 G2 和 G3 NETs，从而实现患者的个体化管理。
